← Leaderboards
Alan R Eastman
Dartmouth College
$10,781,896
Attributed
$10,781,896
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $958.4K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,781,896 · 8
By mechanism
R01$5,879,713 · 3
T32$3,809,404 · 1
P30$753,777 · 2
R21$316,292 · 1
R13$22,710 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsClinical TrialsProgramsMolecularResponseFundingTranslationsAntineoplastic AgentsInvestigationNovel TherapeuticsCancer TherapyTumorResearch PersonnelCollaborationsReportingMemberTranslatingPublicationsFacultyBaseInhibitor/AntagonistCisplatinCancer Center Support GrantApoptosis
Grant awards (55)
Molecular Therapeutics (MT)$67,204
P30 · FY2019 · CA · contact PI
Molecular Therapeutics (MT)$69,654
P30 · FY2018 · CA · contact PI
Molecular Therapeutics (MT)$6,057
P30 · FY2018 · CA · contact PI
Molecular Therapeutics (MT)$5,342
P30 · FY2018 · CA · contact PI
Molecular Therapeutics (MT)$4,790
P30 · FY2018 · CA · contact PI
Molecular Therapeutics (MT)$3,213
P30 · FY2018 · CA · contact PI
Molecular Therapeutics (MT)$1,665
P30 · FY2018 · CA · contact PI
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors$298,566
R01 · FY2017 · CA · contact PI
Molecular Therapeutics (MT)$71,602
P30 · FY2017 · CA · contact PI
Molecular Therapeutics (MT)$1,079
P30 · FY2017 · CA · contact PI
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors$298,566
R01 · FY2016 · CA · contact PI
Molecular Therapeutics (MT)$69,584
P30 · FY2016 · CA · contact PI
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors$298,566
R01 · FY2015 · CA · contact PI
Molecular Therapeutics (MT)$67,204
P30 · FY2015 · CA · contact PI
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors$289,609
R01 · FY2014 · CA · contact PI
MOLECULAR THERAPEUTICS RESEARCH PROGRAM$124,350
P30 · FY2014 · CA · contact PI
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors$298,106
R01 · FY2013 · CA · contact PI
MOLECULAR THERAPEUTICS RESEARCH PROGRAM$47,976
P30 · FY2013 · CA · contact PI
MOLECULAR THERAPEUTICS RESEARCH PROGRAM$51,053
P30 · FY2012 · CA · contact PI
Cancer Biology and Molecular Therapeutics$329,727
T32 · FY2011 · CA · contact PI
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors$294,696
R01 · FY2011 · CA · contact PI
MOLECULAR THERAPEUTICS RESEARCH PROGRAM$50,806
P30 · FY2011 · CA · contact PI
Cancer Biology and Molecular Therapeutics$323,559
T32 · FY2010 · CA · contact PI
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors$303,810
R01 · FY2010 · CA · contact PI
MOLECULAR THERAPEUTICS RESEARCH PROGRAM$57,856
P30 · FY2010 · CA · contact PI
Cancer Biology and Molecular Therapeutics$314,964
T32 · FY2009 · CA · contact PI
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors$303,810
R01 · FY2009 · CA · contact PI
Cancer Biology and Molecular Therapeutics$101,982
T32 · FY2009 · CA · contact PI
MOLECULAR THERAPEUTICS RESEARCH PROGRAM$54,342
P30 · FY2009 · CA · contact PI
Molecular Therapeutics of Cancer Conference$8,000
R13 · FY2009 · CA · contact PI
Cancer Biology and Molecular Therapeutics$317,775
T32 · FY2008 · CA · contact PI
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors$303,810
R01 · FY2008 · CA · contact PI
2006 Molecular Therapeutics of Cancer Gordon Research Conference$4,855
R13 · FY2008 · CA · contact PI
Cell Death Induced by Anticancer Agents$341,132
R01 · FY2007 · CA · contact PI
Cancer Biology and Molecular Therapeutics$308,621
T32 · FY2007 · CA · contact PI
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors$303,810
R01 · FY2007 · CA · contact PI
2006 Molecular Therapeutics of Cancer Gordon Research Conference$4,855
R13 · FY2007 · CA · contact PI
Cancer Biology and Carcinogenesis$359,798
T32 · FY2006 · CA · contact PI
Cell Death Induced by Anticancer Agents$351,321
R01 · FY2006 · CA · contact PI
2006 Molecular Therapeutics of Cancer Gordon Research Conference$5,000
R13 · FY2006 · CA · contact PI
Cancer Biology and Carcinogenesis$401,593
T32 · FY2005 · CA
Cell Death Induced by Anticancer Agents$359,119
R01 · FY2005 · CA
Cancer Biology and Carcinogenesis$401,149
T32 · FY2004 · CA
Cell Death Induced by Anticancer Agents$308,650
R01 · FY2004 · CA
CELL DEATH INDUCED BY ANTICANCER AGENTS$50,000
R01 · FY2004 · CA
Cancer Biology and Carcinogenesis$374,567
T32 · FY2003 · CA
Cell Survival Pathways and Inhibitors in Leukemia$158,000
R21 · FY2003 · CA
Cancer Biology and Carcinogenesis$342,867
T32 · FY2002 · CA
CELL DEATH INDUCED BY ANTICANCER AGENTS$316,168
R01 · FY2002 · CA
Cell Survival Pathways and Inhibitors in Leukemia$158,292
R21 · FY2002 · CA
CELL DEATH INDUCED BY ANTICANCER AGENTS$306,959
R01 · FY2001 · CA
ABROGATION OF CELL CYCLE ARREST BY STAUROSPORINE ANALOGS$281,327
R01 · FY2001 · CA
CELL DEATH INDUCED BY ANTICANCER AGENTS$298,017
R01 · FY2000 · CA
ABROGATION OF CELL CYCLE ARREST BY STAUROSPORINE ANALOGS$273,671
R01 · FY2000 · CA
CANCER BIOLOGY AND CARCINOGENSIS$232,802
T32 · FY2000 · CA